The patient in Dallas being treated for Ebola has been given an experimental drug but remains in critical condition, the hospital said Monday.
Thomas Eric Duncan got a drug called brincidofovir, made by North Carolina-based Chimerix. Doctors stress that they have no idea whether experimental drugs can help Ebola patients. They say supportive care like oxygen and saline solution are as important, if not more important, for their survival.
IN-DEPTH -Maggie Fox
First published October 6 2014, 11:01 AM
Maggie FoxMaggie Fox is senior health writer for NBCNews.com and TODAY.com, writing top news on health policy, medical treatments and disease. She's a former managing editor for healthcare and technology at National Journal and global health and science editor for Reuters based in Washington, D.C. and London.She's reported for news agencies, radio, newspapers, magazines and television from across Asia, the Middle East, Africa and Europe covering news ranging from war to politics and, of course, health and science. Her reporting has taken Maggie to Lebanon, Syria and Libya; to China, South Korea, Thailand, the Philippines and Pakistan; to Bosnia, Croatia and Serbia and to Ireland and Northern Ireland and across the rest of Europe.Maggie has won awards from the Society of Business Editors and Writers, the National Immunization Program, the Overseas Press Club and other organizations. She's done fellowships at Harvard Medical School, the National Institutes of Health and the University of Maryland.
Posted by Unknown on Monday, October 6, 2014 - Rating: 4.5
0 comments "Dallas Ebola Patient Gets Experimental Drug"
Post a Comment